Evaluation of ADM(SC Derm® Recon) in Breast Reconstruction
← catalyst calendarSponsored by DOF Inc. (industry) · DOFG.OL — their whole pipeline →.
Phase
—
Status
Unknown status
Study type
Observational
Enrollment
100estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-12 | actual | When the study began enrolling |
| Primary completion | Jun 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer Female
Intervention
- Other: No intervention conducts.
Primary outcome
what the primary-completion date above is the date OFThe number of occurrences of pre-determined expected adverse events and complications
measured From the day of operation of breast reconstruction to 12 months
Permalink · DOFG.OL's whole pipeline · Catalyst calendar · Every registered study · What changed